| 329 / 329 matched |
| 1 |  | PROSTAGLANDIN A1 /7-[2(R)-(3(S)-Hydroxy-1(E)-octenyl)-5-oxo-3-cyclopenten-1(R)-yl]heptanoic acid / (8R,12S,13E,15S)-15-Hydroxy-9-oxo-10,13-prostadienoic acid (No = XPR1000) |
| 2 |  | PROSTAGLANDIN A2 /7-[2(R)-(3(S)-Hydroxy-1(E)-octenyl)-5-oxo-3-cyclopenten-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1001) |
| 3 |  | 19-HYDROXY-PROSTAGLANDIN A2 /7-[2(R)-(3(S),7-Dihydroxy-1(E)-octenyl)-5-oxo-3-cyclopenten-1(R)-yl]-5(Z)-heptenoic acid / 15(S),19-Dihydroxy-9-oxo-8(12),13-trans-prostadienoic acid (No = XPR1031) |
| 4 |  | PROSTAGLANDIN B1 /7-[2-(3(S)-Hydroxy-1(E)-octenyl)-5-oxo-1-cyclopenten-1-yl]heptanoic acid / (E,S)-15-Hydroxy-9-oxo-8(12),13-prostadienoic acid (No = XPR1100) |
| 5 |  | PROSTAGLANDIN B2 /7-[2-(3(S)-Hydroxy-1(E)-octenyl)-5-oxo-1-cyclopenten-1-yl]-5(Z)-heptenoic acid (No = XPR1101) |
| 6 |  | 19-HYDROXY-PROSTAGLANDIN B2 /7-[2-(3(S),7-Dihydroxy-1(E)-octenyl)-5-oxo-1-cyclopenten-1-yl]-5(Z)-heptenoic acid / 15(S),19-Dihydroxy-9-oxo-5-cis-8(12),13-trans-prostatrienoic acid (No = XPR1131) |
| 7 |  | PROSTAGLANDIN C2 /7-[2-(3(S)-Hydroxy-1(E)-octenyl)-5-oxo-2-cyclopenten-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1201) |
| 8 |  | PROSTAGLANDIN D2 /7-[5(S)-Hydroxy-2(R)-(3(S)-hydroxy-1(E)-octenyl)-3-oxocyclopentan-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1301) |
| 9 |  | PROSTAGLANDIN E1 /7-[3(R)-Hydroxy-2(R)-(3(S)-hydroxy-1(E)-octenyl)-5-oxocyclopentan-1(R)-yl]-heptanoic acid / (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid (No = XPR1400) |
| 10 |  | Prostaglandin E2 /7-[3(R)-Hydroxy-2(R)-(3(S)-hydroxy-1(E)-octenyl-5-oxocyclopentan-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1401) |
| 11 |  | PROSTAGLANDIN E3 /7-[3(R)-Hydroxy-2(R)-(3(S)-hydroxyocta-1(E),5(Z)-dienyl)-5-oxocyclopentan-1(R)-yl]-5(Z)-heptenoic acid / (5Z,8R,11R,12R,13E,15S,17Z)-11,15-Dihydroxy-9-oxo-5,13,17-prostatrienoic acid (No = XPR1402) |
| 12 |  | 15-KETOPROSTAGLANDIN E2 /7-[3(R)-Hydroxy-2(R)-(3-oxo-1(E)-octenyl)-5-oxocyclopentan-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1411) |
| 13 |  | PROSTAGLANDIN E-MAJOR URINARY METABOLITE /8-[2(R)-(2-Carboxyethyl)-5(R)-hydroxy-3-oxocyclopentan-1(R)-yl]-6-oxooctanoic acid (No = XPR1421) |
| 14 |  | 6-KETO-PROSTAGLANDIN E1 /7-[3(R)-Hydroxy-2(R)-(3(S)-hydroxy-1(E)-octenyl)-5-oxocyclopentan-1(R)-yl]-6-oxoheptanoic acid (No = XPR1430) |
| 15 |  | PROSTAGLANDIN F1a /7-[3(R),5(S)-Dihydroxy-2(R)-(3(S)-hydroxy-1(E)-octenyl)cyclopentan-1(R)-yl]-heptanoic acid / (8R,9S,11R,13E,15S)-9,11,15-Trihydroxyprost-13-enoic acid (No = XPR1500) |
| 16 |  | PROSTAGLANDIN F2a /7-[3(R),5(S)-Dihydroxy-2(R)-(3(S)-hydroxy-1(E)-octenylcyclopentan-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1501) |
| 17 |  | PROSTAGLANDIN F3a /7-[3(R),5(S)-Dihydroxy-2(R)-(3(S)-hydroxyocta-1(E),5(Z)-dienyl)cyclopentan-1(R)-yl]-5(Z)-heptenoic acid / (5Z,8R,9S,11R,12R,13E,15S,17Z)-9,11,15-Trihydroxyprosta-5,13,17-trienoic acid (No = XPR1502) |
| 18 |  | 15-KETOPROSTAGLANDIN F2a /7-[3(R),5(S)-Dihydroxy-2(R)-(3-oxo-1(E)-octenyl)cyclopentan-1(R)-yl]-5(Z)-heptenoic acid (No = XPR1511) |
| 19 |  | PROSTAGLANDIN Fa-MAJOR URINARY METABOLITE /8-[2(R)-(2-Carboxyethyl)-3(S),5(R)-dihydroxycyclopentan-1(R)-yl]-6-oxooctanoic acid (No = XPR1521) |
| 20 |  | PROSTAGLANDIN G2 /7-[2(R)-(3(S)-Hydroperoxy-1(E)-octenyl)-1(R),4(S)-5,6-dioxabicyclo[2.2.1]-heptan-3(R)-yl]-5(Z)-heptenoic acid (No = XPR1601) |